Ceregene Discovers $32M

San Diego-based Ceregene has closed a $32M Series B funding round from Alta Partners and MPM Capital, with participation by Hamilton Apex and California Technology Ventures. Public company Cell Genesys (CEGE) which is a majority owner of Ceregene converted their bridge loan into Series B shares. Ceregene is developing drug candidates targeted at Parkinson's disease, Lou Gehrig's disease, and Alzeheimer's. More information »